We are live on
!
Find out more
CC
Casdin Capital Portfolio holdings
AUM
$1.32B
1-Year Est. Return
76.62%
This Fund
S&P 500
This Quarter
Est. Return
+60.74%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.09B
AUM Growth
+$121M
(+13%)
Cap. Flow
-$94.6M
Cap. Flow
% of AUM
-8.7%
Top 10 Holdings %
Top 10 Hldgs %
62.33%
Holding
35
New
2
Increased
10
Reduced
8
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BLUE
bluebird bio
BLUE
|
+$30M |
| 2 |
Denali Therapeutics
DNLI
|
+$9.99M |
| 3 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$7.37M |
| 4 |
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
|
+$6.2M |
| 5 |
CareDx
CDNA
|
+$4.59M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$83.7M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$21.2M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
+$20.9M |
| 4 |
Q32 Bio
QTTB
|
+$14.8M |
| 5 |
Editas Medicine
EDIT
|
+$9.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
CALL
Gilead Sciences
GILD
$163B
| $13M | 1.2% |
+200,000
| New | +$13M |
|
|
SGMO
27
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $12.2M | 1.12% |
1,455,000
| – | – |
|
|
ORTX
28
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $11.3M | 1.04% |
82,000
+51,000
| +165% | +$6.2M |
|
29
Twist Bioscience
TWST
$6.29B
| $6.3M | 0.58% |
300,000
| – | – |
|
|
TPTX
30
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $4.67M | 0.43% |
75,000
| – | – |
|
|
BMY.RT
31
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $4.51M | 0.42% |
+1,500,000
| New | +$3.9M |
|
32
Stoke Therapeutics
STOK
$1.84B
| $3.68M | 0.34% |
130,000
| – | – |
|
|
33
Editas Medicine
EDIT
$407M
| – | – |
-415,000
| Closed | -$9.44M |
|
|
34
Q32 Bio
QTTB
$450M
| – | – |
-45,556
| Closed | -$14.8M |
|
|
ONCE
35
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| – | – |
-863,300
| Closed | -$83.7M |
|
Similar funds
MDSL
CP
HCM
MRL
SWM
B
WGAM
CRAM
Casdin Capital's Q4 2019 Portfolio in Review
As of Q4 2019, Casdin Capital held 35 positions worth $1.09B, up 13% from $966M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Casdin Capital withdrew a net $94.6M in Q4 2019, closing 3 positions and reducing 8 holdings. Its most notable exit was Spark Therapeutics, Inc. Common Stock, an estimated $83.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier.
Against the trend, Casdin Capital opened a new position in Bristol-Myers Squibb Company Contingent Value Rights worth $4.51M.
- Casdin Capital's largest Q4 2019 buy was Bristol-Myers Squibb Company Contingent Value Rights: 1,500,000 shares worth $4.51M.
- Casdin Capital added most to bluebird bio in Q4 2019, an estimated $30M increase.
- Casdin Capital's biggest Q4 2019 reduction was Sarepta Therapeutics, cutting an estimated $21.2M.
- Casdin Capital fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $83.7M.
- Casdin Capital's ten largest holdings make up 62% of its $1.09B portfolio in Q4 2019.
- Casdin Capital opened 2 new positions and closed 3 in Q4 2019.
- Casdin Capital's portfolio value rose 13% quarter-over-quarter to $1.09B.
Based on Casdin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.